1527MO Biomarkers of response and hyperprogression in patients with sarcoma treated with checkpoint blockade
Nicholas D. Klemen(Yale University), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Sinchun Hwang(Memorial Sloan Kettering Cancer Center), William D. Tap(Memorial Sloan Kettering Cancer Center), Katherine A. Thornton(Memorial Sloan Kettering Cancer Center), Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Mark T.A. Donoghue(Memorial Sloan Kettering Cancer Center), Edmund K. Bartlett(Memorial Sloan Kettering Cancer Center), Allison L. Richards(Memorial Sloan Kettering Cancer Center), Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Benjamin A. Nacev(University of Pittsburgh), Evan Rosenbaum(Memorial Sloan Kettering Cancer Center), Martina Bradić(New York University), Sujana Movva(Memorial Sloan Kettering Cancer Center), Mary Louise Keohan(Roche (Switzerland)), Samuel Singer(Memorial Sloan Kettering Cancer Center), Ciara M. Kelly(Memorial Sloan Kettering Cancer Center), Jason E. Chan(Memorial Sloan Kettering Cancer Center), Ping Chi(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k